<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; PDLI</title>
	<atom:link href="http://www.stockbloghub.com/tag/pdli/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SKM) Don&#8217;t Get Trapped by High Dividends</title>
		<link>http://www.stockbloghub.com/2011/12/14/skm-dont-get-trapped-by-high-dividends/88478</link>
		<comments>http://www.stockbloghub.com/2011/12/14/skm-dont-get-trapped-by-high-dividends/88478#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:04:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Telecom Services - Foreign]]></category>
		<category><![CDATA[Kayne Anderson Energy Development Company]]></category>
		<category><![CDATA[KED]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>
		<category><![CDATA[SK Telecom Company Limited]]></category>
		<category><![CDATA[SKM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88478</guid>
		<description><![CDATA[High-dividend stocks are always popular, and why not? When the market is fickle and when it’s difficult to earn steadily from price movement of stocks, a high cash-dividend payer could be a good bet. Cash dividends could return more than what you would have earned had you saved your money in a bank. But choosing a stock only on the basis of how high a dividend it pays may not always be a good idea. You may even find yourself trapped. How Come?   Before selecting a dividend-stock, many investors’ basic calculations focus primarily on dividend yield (annual dividend per share/stock’s price per share) as this represents the percentage return on the invested amount. Besides reflecting the percentage return, dividend yield also gives a fair idea of whether selecting a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/skm-dont-get-trapped-by-high-dividends/88478/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Revenues Fall &#8211; Outlook Improves</title>
		<link>http://www.stockbloghub.com/2011/05/03/azn-astrazeneca-revenues-fall-outlook-improves/73038</link>
		<comments>http://www.stockbloghub.com/2011/05/03/azn-astrazeneca-revenues-fall-outlook-improves/73038#comments</comments>
		<pubDate>Tue, 03 May 2011 18:03:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73038</guid>
		<description><![CDATA[AstraZeneca plc (AZN) reported first-quarter fiscal 2011 core earnings of $2.23 per American Depositary Share (ADS), reflecting an increase of 10% (at constant exchange rates [CER]) from the prior-year quarter. The Zacks Consensus Estimate for the reported quarter was $2.04 per share. Including one-time items, earnings came in at $2.08, up 10%. Despite lower revenues, earnings climbed as a result of lower tax rate and lower number of shares outstanding. Revenues AstraZeneca’s first quarter revenues declined 4% year over year to $8.3 billion owing to intense generic competition and government price interventions. However, revenues were in line with the Zacks Consensus Estimate. Generic competition for major products in the US and the impact of the healthcare reform led to an 11% slide in US revenues. The Rest of the World ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/azn-astrazeneca-revenues-fall-outlook-improves/73038/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PDLI) PDL BioPharma Ramps Up Earnings &#8211; Settles Disputes</title>
		<link>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805</link>
		<comments>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805#comments</comments>
		<pubDate>Mon, 07 Mar 2011 18:02:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67805</guid>
		<description><![CDATA[PDL BioPharma Inc. (PDLI) posted fourth quarter earnings of 20 cents per share, above the year-ago figure of 17 cents. Higher revenues boosted earnings in the quarter. Earnings per share were, however, a penny short of the Zacks Consensus Estimate of 21 cents. For full year 2010, PDL reported earnings per share of 97 cents, down from $1.06 per share in 2009 but ahead of the Zacks Consensus Estimate of 90 cents. Full year 2010 revenues of $345 million were well above the prior-year figure of $318.2 million. Revenues also beat the Zacks Consensus Estimate of $343 million. 2009 revenues included royalties from MedImmune, a subsidiary of AstraZeneca (AZN), on sales of Synagis, which PDL no longer receives. Excluding this revenue, sales were up 30% over the prior year. Quarterly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/07/pdli-pdl-biopharma-ramps-up-earnings-settles-disputes/67805/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMZN) Company News for March 01, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/03/03/amzn-company-news-for-march-01-2011-corporate-summary/67806</link>
		<comments>http://www.stockbloghub.com/2011/03/03/amzn-company-news-for-march-01-2011-corporate-summary/67806#comments</comments>
		<pubDate>Thu, 03 Mar 2011 21:39:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Catalog & Mail Order Houses]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Amazon.com Inc]]></category>
		<category><![CDATA[Amerigon Inc]]></category>
		<category><![CDATA[AMZN]]></category>
		<category><![CDATA[ARGN]]></category>
		<category><![CDATA[BID]]></category>
		<category><![CDATA[KCP]]></category>
		<category><![CDATA[Kenneth Cole Productions Inc]]></category>
		<category><![CDATA[MEMC Electronic Materials Inc.]]></category>
		<category><![CDATA[Nationwide Health Properties Inc]]></category>
		<category><![CDATA[NHP]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>
		<category><![CDATA[Sotheby's]]></category>
		<category><![CDATA[TIE]]></category>
		<category><![CDATA[Titanium Metals Corporation]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[Ventas Inc.]]></category>
		<category><![CDATA[VTR]]></category>
		<category><![CDATA[WFR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67806</guid>
		<description><![CDATA[• Board of Directors of both Ventas, Inc. (NYSE:VTR) and Nationwide Health Properties, Inc. (NYSE:NHP) have approved a definitive merger agreement between the two companies • Titanium Metals (NYSE:TIE) reported Q4 EPS of $0.13, in line with the Zacks Consensus Estimate of $0.13 per share. Revenues for the quarter rose 18% year-over-year to $217.3 million, lower than the Zacks Consensus Estimate of $219.0 million • Sotheby’s (NYSE:BID) reported Q4 EPS of $1.38, in line with the Zacks Consensus Estimate of $1.38 per share. Revenues for the quarter rose 46% year-over-year to $318.5 million, above the Zacks Consensus Estimate of $298.0 million • UBS (NYSE:UBS) downgraded Amazon.com, Inc. (NASDAQ:AMZN) to a ‘neutral’ from a ‘buy’ rating • On Monday, manufacturer of car seats Amerigon Inc (NASDAQ:ARGN) said it would buy 76.6% of Germany’s WET Automotive Systems ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/03/amzn-company-news-for-march-01-2011-corporate-summary/67806/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PDLI) PDL BioPharma Meets Earnings Forecast &#8211; Beats Revenue Forecast</title>
		<link>http://www.stockbloghub.com/2010/11/17/pdli-pdl-biopharma-meets-earnings-forecast-beats-revenue-forecast/59524</link>
		<comments>http://www.stockbloghub.com/2010/11/17/pdli-pdl-biopharma-meets-earnings-forecast-beats-revenue-forecast/59524#comments</comments>
		<pubDate>Thu, 18 Nov 2010 05:07:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59524</guid>
		<description><![CDATA[PDL BioPharma Inc. (PDLI) posted third quarter earnings of 25 cents per share, in line with the Zacks Consensus Estimate, but below the year-ago figure of 29 cents. Earnings declined in the quarter, despite the increase in revenue, due to higher selling and general expenses. Quarterly Details Third quarter revenue of $86.4 million was higher than the Zacks Consensus Estimate of $84 million and about 21% above the year-ago revenue. The top-line increase resulted from higher 2Q10 sales of Roche’s (RHHBY) Avastin, Herceptin, and Lucentis, and Biogen/Elan’s (BIIB/ELN) Tysabri, on which PDL BioPharma received royalties in 3Q10. Revenue was, however, in line with the company’s guidance of $86 million provided in September 2010. Quarterly general and administrative expenses increased from $5.3 million in the year-earlier quarter to $11.1 million in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/17/pdli-pdl-biopharma-meets-earnings-forecast-beats-revenue-forecast/59524/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PDLI) PDL BioPharma Announces Third-Quarter Outlook</title>
		<link>http://www.stockbloghub.com/2010/09/07/pdli-pdl-biopharma-announces-third-quarter-outlook/50221</link>
		<comments>http://www.stockbloghub.com/2010/09/07/pdli-pdl-biopharma-announces-third-quarter-outlook/50221#comments</comments>
		<pubDate>Tue, 07 Sep 2010 13:48:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50221</guid>
		<description><![CDATA[PDL BioPharma Inc. (PDLI) recently announced that it expects to generate third-quarter 2010 (ending September 30) revenue of $86.0 million, representing an increase of 20% over the year-ago revenue of $71.4 million. The increase is primarily attributable to higher sales of Avastin, Herceptin, Lucentis and Tysabri during the second quarter, on which PDL BioPharma will receive royalties in the third quarter. The Zacks Consensus Estimate for the third quarter is $3 million below the company&#8217;s revenue guidance. The third quarter revenue outlook is inclusive of the $2.9 million earned by the company on Eurodollar foreign currency hedging contracts, initiated in January 2010. PDL BioPharma derives royalty revenue from the worldwide net sales of humanized antibody products, which include Roche Holdings Ltd.&#8217;s (RHHBY) Avastin, Herceptin, Xolair, and Lucentis Elan Corporation plc&#8216;s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/07/pdli-pdl-biopharma-announces-third-quarter-outlook/50221/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PDLI) PDL BioPharma&#8217;s Fourth Quarter Falls Short</title>
		<link>http://www.stockbloghub.com/2010/03/03/pdli-pdl-biopharmas-fourth-quarter-falls-short/29563</link>
		<comments>http://www.stockbloghub.com/2010/03/03/pdli-pdl-biopharmas-fourth-quarter-falls-short/29563#comments</comments>
		<pubDate>Wed, 03 Mar 2010 21:44:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29563</guid>
		<description><![CDATA[PDL BioPharma, Inc. (PDLI) reported fourth-quarter fiscal 2009 earnings of 17 cents per share, 2 cents below the Zacks Consensus Estimate. The company earned 34 cents (from continuing operations) in the year-ago quarter. Results in the quarter were hurt by lower revenues. Quarterly Results Total revenues in the reported quarter stood at $58.3 million as against $68.7 million in the year-ago quarter, down approximately 15.1%. The revenues for the fourth quarter of 2008 included the first of the two $12.5 million settlement installments from Alexion Pharmaceuticals (ALXN). The payment for the second installment was received and recognized in the second quarter of 2009. General and administrative expenses in the reported quarter fell to $5.5 million from $15.9 million in the year-ago quarter. The huge fall was primarily attributable to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/pdli-pdl-biopharmas-fourth-quarter-falls-short/29563/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

